Caladrius three major Biotech Conferences in November.
Caladrius Biosciences increases Market Awareness with three major
Biotech Conferences in November.



Caladrius Biosciences to Present at Multiple Upcoming November Conference Presentations to highlight Company's therapeutic
Development Programs and 

BASKING RIDGE, N.J. (November 2, 2015) – Caladrius Biosciences, Inc. (NASDAQ: CLBS) (“Caladrius”), a company combining a leading cell therapy service provider with a therapeutics pipeline including a Phase 3 clinical program in immuno-oncology and a portfolio of earlier clinical phase projects in immune modulation and ischemic repair, announces today that the Company’s leadership, experts and related research investigators will present at three conferences in November.
SITC 2015 30th Anniversary Annual Meeting & Associated Programs
  • Website:
  • Venue: Gaylord National Hotel & Convention Center, National Harbor, Maryland
  • Date and Time: Thursday, November 5, 2015, 4:00 PM ET
Session 1
  • Presenter: Robert Dillman, MD, Vice President, Oncology
  • Poster Topic: Superiority of Dendritic Cell Vaccine vs Tumor Cell Vaccine: Survival by stratification subsets in MACVAC randomized phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines

Session 2
  • Presenter: Gabriel Nistor, MD, Vice President, Research
  • Poster Topic: Functional Properties of Patient-Derived Melanoma Cancer Stem Cells
American Heart Association Scientific Sessions 2015

Session 1
  • Date and Time: Monday, November 9, 2015, 9:00 AM ET
  • Session Moderator: Douglas Losordo, MD, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
  • Topic: Biological Therapies in Peripheral Artery Disease: Current Standards and Concepts

Session 2
  • Date and Time: Monday, November 9, 2015, 9:24 AM ET
  • Presenter: Douglas Losordo, MD, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
  • Topic: CD34 Positive Cells in PAD: Current Evidence

Session 3
  • Date and Time: Monday, November 9, 2015, 4:15 PM ET
  • Presenter: Arshed A. Quyyumi, MD, Professor of Medicine at Emory University, Lead Principal Investigator of PreSERVE-AMI study
  • Topic: Infused CD34 Cell Dose, Not Bone Marrow CD34+ Cell Content, Improves Clinical Outcomes and LVEF in Patients with Left Ventricular Dysfunction Post STEMI: Results of the PreSERVE-AMI trial
Society for Melanoma Research 2015 Congress
  • Website:
  • Venue: San Francisco Marriott Marquis, San Francisco, California
  • Date and Time: Wednesday, November 18, 2015, 7:30 PM PT

Session 1
  • Presenter: Robert Dillman, MD, Vice President, Oncology
  • Poster Topic: Superiority in a Randomized Trial of Patient-Specific Dendritic Cell/Tumor Cell Vaccines vs Tumor Cell Vaccines in Subsets Defined by Disease Stage, Tumor Measurability, and Lactate Dehydrogenase (LDH) level

Session 2
  • Presenter: Gabriel Nistor, MD, Vice President, Research
  • Poster Topic: Mechanism of Action of CLBS20, A Patient-Specific Immunotherapy Targeting Metastatic Melanoma
About Caladrius Biosciences
Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius combines a leading cell therapy service provider with a development pipeline including late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for immunomodulation and ischemic repair. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. For more information, visit

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, the Company’s ability to develop and grow its business, the successful development of cellular therapies with respect to the Company’s research and development and clinical evaluation efforts in connection with the Company’s Immuno-oncology Program, Immune Modulation Program, Ischemic Repair Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company’s wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT, as well as its efforts to expand its capabilities into the cell therapy tools market. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 2, 2015, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.

Past Press Releases

October 29, 2015
Caladrius Biosciences to Host Third Quarter 2015 Financial Results Conference Call on November 5 at 5:00 pm

October 8, 2015
Caladrius Biosciences Announces Management and Board Changes

October 1, 2015
Caladrius Biosciences to Present at Multiple Upcoming October Conferences



November 18, 2015
Society for Melanoma Research 2015 Congress
November 9, 2015
American Heart Association Scientific Sessions 2015
November 5, 2015
SITC 2015 30th Anniversary Annual Meeting & Associated Programs
Please visit our research service site We would appreciate if you could pass our newsletter on to your friends and colleagues and naturally, we always appreciate your feedback and comments.
About SWI
SWI is a leading edge PR, Information Marketing and Research firm with a highly frequented web site, its "Rise Above The Noise" newsletter and SWI Research site These services provide readers with information and research on new, often undiscovered and promising public companies. The QuickPicks section on the SWI site represents the consolidated opinions of carefully selected financial analyst reports and opinions from credible Wall Street firms that we respect and frequently sample. Our weekly SWI QuickPicks  Ratings Report keeps you informed about newly SWI initiated stocks and potential upgrades and downgrades in the QuickPicks section. We are not being compensated by these companies and do not necessarily hold positions in any of these stocks.  You can conveniently follow the live links for each of these stocks on for more detail.  SWI's  "Portfolio Performance Report" periodically reports about the performance of the stocks that we have purchased in our portfolio. typically hold and may be trading.  Please do not miss the wealth of frequently updated news, research reports and other valuable information elsewhere on SWI, especially for the stocks on our WatchIndex page. Watch a full range of CEO and analyst interviews on our Strategic Partner site  
Google +
Good luck and please pass this newsletter on to a friend
to continue building our community.

StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise) of the information provided in the publications for its Stock Watch List or on its web sites. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrants any results from use of the information. We have contracted with some of the companies we present on SWI or in the SWI Newsletter as public relations consultants to keep the market and especially our subscribers informed about the companies and may have been compensated in cash and/or stock and stock options, which may be considered a potential conflict of interest. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or in any of its other publications. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice.

Copyright © 2015 StockWatchIndex, LLC, All rights reserved.

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp